2021-3-2 · Nat. Rev. Drug Discov. Nat. Rev. Drug Discov. 2021-03-03 2021-03-03 15 58 30 82 0 Nature reviews. Drug discovery
2021-3-31 · The high rate of new drug approvals in 2018 (Nat. Rev. Drug Discov. 18 328 2019) continued in 2019. To investigate the mechanistic novelty of new drugs approved in the United States the European Union and Japan last year we annotated their mechanism of action (MoA) biomolecular targets (as defined in Nat. Rev. Drug Discov.
2021-2-11 · The most successful oncology drug portfolios of the past decade. February 03 2021 MEDLINE Abstract Trends in peptide drug discovery. February 03 2021 MEDLINE Abstract Natural products in drug discovery advances and opportunities. January 28 2021 MEDLINE Abstract Teaching old brains new immune tricks. January 28 2021
Nat Rev Drug Discov 3 1047-1056. Article. Jan 2005. Kapil Dev. Modulating protein-protein interactions involved in disease pathways is an attractive strategy for developing drugs but remains a
Journal Abbreviation NAT REV DRUG DISCOV Journal ISSN 1474-1776
2021-7-4 · NAT REV DRUG DISCOV SCI " NAT REV DRUG DISCOV " " NAT REV DRUG DISCOV "
2021-2-11 · The breast cancer drug market. January 22 2021 MEDLINE Abstract Epigenetics and beyond targeting writers of protein lysine methylation to treat disease. January 19 2021
2021-3-2 · Nat. Rev. Drug Discov. . Nature Nature Review Drug Discovery Trends in peptide drug discovery .
2017-12-15 · Esch E. W. Bahinski A. Huh D. Organs-on-chips at the frontiers of drug discovery. Nat. Rev. Drug Discov. 14 248–260 (2015).
2021-2-11 · The most successful oncology drug portfolios of the past decade. February 03 2021 MEDLINE Abstract Trends in peptide drug discovery. February 03 2021 MEDLINE Abstract Natural products in drug discovery advances and opportunities. January 28 2021 MEDLINE Abstract Teaching old brains new immune tricks. January 28 2021
2021-3-2 · Nat. Rev. Drug Discov. Nat. Rev. Drug Discov. 2021-03-03 2021-03-03 15 58 30 82 0 Nature reviews. Drug discovery
2021-2-11 · The breast cancer drug market. January 22 2021 MEDLINE Abstract Epigenetics and beyond targeting writers of protein lysine methylation to treat disease. January 19 2021
Nat Rev Drug Discov. Author manuscript available in PMC 2018 Apr 19. Published in final edited form as Nat Rev Drug Discov. 2018 Apr 17(4) 261–279. Published online 2018 Jan 12.
NAT REV DRUG DISCOV NATURE REVIEWS DRUG DISCOVERY MI 2.72131 H 114 greenSCI SCIJOURNAL 36 1 1 /1 15/
2021-7-4 · NAT REV DRUG DISCOV SCI " NAT REV DRUG DISCOV " " NAT REV DRUG DISCOV "
In this Perspective we summarize key trends in peptide drug discovery and development covering the early efforts focused on human hormones elegant medicinal chemistry and rational design strategies peptide drugs derived from nature and major breakthroughs in molecular biology and peptide chemistry that continue to advance the field.
2021-3-31 · The high rate of new drug approvals in 2018 (Nat. Rev. Drug Discov. 18 328 2019) continued in 2019. To investigate the mechanistic novelty of new drugs approved in the United States the European Union and Japan last year we annotated their mechanism of action (MoA) biomolecular targets (as defined in Nat. Rev. Drug Discov.
11 rows · Journal Abbreviation NAT REV DRUG DISCOV Journal ISSN 1474-1776
Nat Rev Drug Discov. Author manuscript available in PMC 2018 Apr 19. Published in final edited form as Nat Rev Drug Discov. 2018 Apr 17(4) 261–279. Published online 2018 Jan 12.
2012-7-19 · Nat Rev drug discov. 7 10 (2008) 841853 Lee MJ. et al. Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol. 20 (2008) 639649 Luger K. et al. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 389 (1997) 251260 Mai A. The therapeutic uses of chromatin-modifying agents. Expert Opin. Ther
Copeland R. A. Pompliano D. L. Meek T. D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 2006 5 730-739.
2012-7-19 · Nat Rev drug discov. 7 10 (2008) 841853 Lee MJ. et al. Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol. 20 (2008) 639649 Luger K. et al. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 389 (1997) 251260 Mai A. The therapeutic uses of chromatin-modifying agents. Expert Opin. Ther
Nat Rev Drug Discov 3 1047-1056. Article. Jan 2005. Kapil Dev. Modulating protein-protein interactions involved in disease pathways is an attractive strategy for developing drugs but remains a
Journal Abbreviation NAT REV DRUG DISCOV Journal ISSN 1474-1776
2016-3-3 · Nat Rev Drug Discov 11(7) 527-540. Biologics such as monoclonal antibodies are much more complex than small-molecule drugs which raises challenging questions for the development and regulatory evaluation of follow-on versions of such
2021-3-12 · Nat Rev Drug Discov CDC 42BPA/MRCKalpha akinasetargetfor brain ovarian and skin cancers C DC 42BPA/MRCKα . -
NAT REV DRUG DISCOV NATURE REVIEWS DRUG DISCOVERY 2002 36 Monthly 1.5
2021-7-4 · NAT REV DRUG DISCOV SCI " NAT REV DRUG DISCOV " " NAT REV DRUG DISCOV "
Journal Abbreviation NAT REV DRUG DISCOV Journal ISSN 1474-1776
BQ+ Medical not only produce components for manufacturers all over the world, but also provide private label manufacturing for leading brand distributors in different countries.
8,Cheye Road,Songjiang District,Shanghai 201611 China.
Tel: 86-021-57743953
Email: [email protected]
Copyright © BQ PLUS MEDICAL CO., LTDSitemap | Contact Us |
